학술논문
LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S1307-S1307
Subject
Language
ISSN
0923-7534